AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
=== RNA interference === RNA interference (RNAi) uses segments of RNA to fatally silence crucial insect genes. In 2024 two uses of RNAi have been registered by the authorities for use: Genetic modification of a crop to introduce a gene coding for an RNAi fragment and spraying double stranded RNA fragments onto a field. Monsanto introduced the trait DvSnf7 which expresses a double-stranded RNA transcript containing a 240 bp fragment of the WCR Snf7 gene of the Western Corn Rootworm. GreenLight Biosciences introduced Ledprona, a formulation of double stranded RNA as a spray for potato fields. It targets the essential gene for proteasome subunit beta type-5 (PSMB5) in the Colorado potato beetle.
August 3 – Allan Nascimento, 34, mixed martial artist (UFC). August 18 – Glória Menezes, 91, actress. September 9 – Jackson Nascimento, 102, football player (Athletico Paranaense, Corinthians) and manager (Athletico Paranaense). September 14 – Aracy Amaral, 96, art historian and curator, director of the Pinacoteca do Estado de São Paulo (1975–1979) and the Museum of Contemporary Art, University of São Paulo (1982–1986). September 15 – Amelinha Teles, 81, journalist and political activist. Paulo César Martin, 62, journalist and radio host (Folha de S.Paulo, TV Globo, Conrad Editora). September 22 – Rick Sollo, 59, singer-songwriter (Rick & Renner) and Sertanejo music producer. September 26 – Pedro Antônio Marchetti Fedalto, 100, Roman Catholic prelate, auxiliary bishop (1966–1970) and archbishop (1970–2004) of Curitiba.
Bruker Corporation is an American manufacturer of scientific instruments for molecular and materials research, as well as for industrial and applied analysis. It is headquartered in Billerica, Massachusetts, and is the publicly traded parent company of Bruker Scientific Instruments (Bruker AXS, Bruker BioSpin, Bruker Daltonics and Bruker Optics) and Bruker Energy & Supercon Technologies (BEST) divisions. In April 2010, Bruker created a Chemical Analysis Division (headquartered in Fremont, CA) under the Bruker Daltonics subsidiary. This division contains three former Varian product lines: ICPMS systems, laboratory gas chromatography (GC), and GC-triple quadrupole mass spectrometer (originally designed by Bear Instruments and acquired by Varian in 2001). In 2012, it sponsored the Fritz Feigl Prize, and since 1999 the company has also sponsored the Günther Laukien Prize.
Sources: en.wikipedia.org
An alternative latex method sometimes used in China in the past is to cut off the poppy heads, run a large needle through them, and collect the dried latex 24 to 48 hours later. In India, opium harvested by licensed poppy farmers is dehydrated to uniform levels of hydration at government processing centers and then sold to pharmaceutical companies that extract morphine from the opium. However, in Turkey and Tasmania, morphine is obtained by harvesting and processing the fully mature dry seed pods with attached stalks, called poppy straw. In Turkey, a water extraction process is used, while in Tasmania, a solvent extraction process is used. Opium poppy contains at least 50 different alkaloids, but most of them are of low concentration. Morphine is the principal alkaloid in raw opium and constitutes roughly 8–19% of opium by dry weight (depending on growing conditions). Some purpose-developed strains of poppy now produce opium that is up to 26% morphine by weight. A rough rule of thumb to determine the morphine content of pulverised dried poppy straw is to divide the percentage expected for the strain or crop via the latex method by eight or an empirically determined factor, which is often in the range of 5 to 15. The Norman strain of P. somniferum, also developed in Tasmania, produces as little as 0.04% morphine but with much higher amounts of thebaine and oripavine, which can be used to synthesise semi-synthetic opioids as well as other drugs like stimulants, emetics, opioid antagonists, anticholinergics, and smooth-muscle agents.
=== Cancer treatment side effects === LLLT has been studied as a way to reduce pain and swelling in breast-cancer related lymphedema. The 2015 systematic review and meta-analysis by Smoot, Chiavola-Larson, et al found "Moderate-strength evidence supports LLLT in the management of [breast cancer related lymphoedema], with […] reductions in volume and pain immediately after conclusion of LLLT treatments. Greater reductions in volume [of lymph nodes or surrounding tissues] were found with the use of LLLT than in treatments without it."
Guanylate cyclase (EC 4.6.1.2, also known as guanyl cyclase, guanylyl cyclase, or GC; systematic name GTP diphosphate-lyase (cyclizing; 3′,5′-cyclic-GMP-forming)) is a lyase enzyme that converts guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP) and pyrophosphate:
=== December === 1 December – Everton Football Club launch an appeal against the decision to dock them ten Premier League points. 2 December – Havering London Borough Council reverses its decision to cancel the display of Hanukkah candles outside its town hall, having previously said the display would not go ahead because of "escalating tensions from the conflict in the Middle East". Police declare a major incident in Cumbria, which is affected by heavy snowfall. As much as 30 cm has fallen by the following day. 5 December – Junior doctors in England will stage further strike action after rejecting the latest pay offer, the British Medical Association confirms, with a three-day strike scheduled to begin on 20 December and a six-day strike scheduled to begin on 3 January 2024. A woman, later named as Lianne Gordon, is shot dead in an incident in east London. A teenage boy and a man are also injured in the shooting. 6 December – Mayor of the West Midlands Andy Street confirms the Home Secretary has authorised his application to have the powers of the West Midlands Police and Crime Commissioner subsumed into his mayoral role from May 2024. 7 December – An inquest into the death of Ruth Perry rules that an Ofsted report "likely contributed" to the head teacher taking her life in January 2023. Six former Metropolitan Police officers are given suspended sentences after sending racist, sexist and homophobic WhatsApp messages. 9 December – A 16-year-old boy is charged with the murder of Lianne Gordon.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.